News Center
livzon was selected for the S&P Global "2024 Sustainable Development Yearbook" and awarded the title of "Best Progress Company in the Industry".
Release time:
2024-02-20
Recently, LIZHU was selected for the first time in the "Sustainability Yearbook 2024" published by S&P Global. Among more than 9,400 companies evaluated globally, only three Chinese pharmaceutical companies were included in the yearbook, and LIZHU is one of them.
In addition, LIZHU is the only company in the global pharmaceutical industry to be awarded the title of "Industry Mover" for the year 2023. According to the selection criteria of the yearbook, only those member companies that participated in this year's and last year's S&P Global Corporate Sustainability Assessment (CSA) and were already included in the yearbook, and achieved the largest improvement in CSA scores in their industry with an increase of no less than 5%, can be recognized as "Industry Mover." This honor once again proves LIZHU's outstanding achievements in ESG work and its determination to stay at the forefront of global corporate sustainability.
S&P Global publishes the "Sustainability Yearbook" annually, and this year marks the 20th anniversary of its continuous publication. The yearbook summarizes the main sustainability risks and opportunities in various industries over the past year, aiming to identify and recognize companies that excel in sustainability performance across different sectors, receiving high attention from global enterprises and stakeholders. A company's S&P CSA score must rank in the top 15% of its industry, be no less than 30 points, and have a gap of less than 30 points from the highest score in the industry to be included in the "Sustainability Yearbook."
Among the 9,400 companies participating in the 2023 CSA assessment across 62 industries globally, a total of 759 companies were included in the yearbook, including 75 companies from China (including Hong Kong, Macau, and Taiwan). In the pharmaceutical industry, a total of 235 pharmaceutical companies participated, and ultimately 22 companies were included in the yearbook, of which 3 are Chinese pharmaceutical companies (including Hong Kong, Macau, and Taiwan).
In 2023, LIZHU was also awarded numerous honors, including MSCI ESG AAA rating, Wind ESG AA rating, Guozheng ESG AAA rating, "Top 20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies in 2023," and "Top 100 Best Practices in ESG of Chinese Listed Companies in 2023."
The level of ESG governance is currently an important consideration for global investors in measuring the sustainability and social responsibility of listed companies, and ESG rating performance intuitively reflects the company's ESG governance level. LIZHU always adheres to the vision of "being a leader in the pharmaceutical industry," with the mission of "putting patient quality of life first," placing great importance on corporate ESG management, establishing an ESG governance structure with the board of directors as the highest decision-making body, and incorporating ESG assessment indicators into the personal performance evaluation of ESG working group members, creating a compensation mechanism linked to sustainable development. Through top-down policy implementation and effective ESG management and improvement actions, a solid development core for LIZHU's sustainable development work has been established.
About S&P Global Corporate Sustainability Assessment
In 2023, approximately 13,000 companies were invited to participate in the S&P Global Corporate Sustainability Assessment. The S&P Global Corporate Sustainability Assessment ("CSA") is one of the largest annual assessments of corporate sustainability practices globally. By quantifying and scoring various ESG management and performance indicators of companies, it comprehensively reflects the level of ESG management and information disclosure of companies, serving as an important basis for global investors' investment decisions and data analysis. The CSA covers 62 different industry-specific sustainability standards, characterized by comprehensive indicators, detailed granularity, strict standards, and transparent data, effectively identifying companies that actively respond to sustainability opportunities and challenges, and is an important basis for companies to be included in the Dow Jones Sustainability Index (DJSI) and other S&P ESG series indices. For the pharmaceutical industry, S&P has set the scoring weights for environmental, social, governance, and economic dimensions at 13%, 42%, and 45%, respectively.
Related Information